



## ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

# CLINICAL TRIAL PROGRESSING ON TARGET AND ASA MILESTONE ACHIEVED

**EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”)**, is pleased to provide an update on its clinical trial and achievement of an important technical development milestone.

The pre-validation phase of the clinical trial is on schedule, with approximately half of the 30 participants for Stage 1 (healthy volunteers) having now been successfully enrolled. It is anticipated that all 30 participants will be enrolled in the coming weeks, at which point Stage 2 of the trial will be activated, involving up to 150 acute stroke/stroke mimic patients. The device’s ease of use by operators and comfort for participants has been observed, while no device-related adverse events have been reported.

The Company is also pleased to advise that it has successfully achieved an important technical development milestone for its portable imaging devices under the Commonwealth of Australia Medical Research Future Fund (MRFF) program in partnership with the Australian Stroke Alliance (ASA), “Technical Validation of Algorithms commenced and in progress”. This has triggered a \$600,000 milestone payment from the ASA.

The milestone activities focused on extensive benchtop (phantom brain and complex simulation) experiments designed to mimic clinical use of the EMVision technology to support stroke subtype diagnosis. Pleasingly, both the existing 1<sup>st</sup> Gen system and the 2<sup>nd</sup> Gen road and air ambulance device, currently under development, demonstrated high levels of performance in these experiments. As a result, a full 3D 2<sup>nd</sup> Gen antenna array has been fabricated for further verification and development. EMVision is targeting road/air ambulance trials next year.

**EMVision CEO, Dr Ron Weinberger commented:** “We are pleased that our trial is progressing as planned, especially given it commenced just before the holiday period. We have strong clinical engagement and the ease of training and use of our device, along with the speed of scanning, has certainly helped with the process. The testing conducted as part of our ASA milestones has shown encouraging benchtop results from our system enhancements which bodes well for our clinical trials. We are excited with the progress being made with our 2<sup>nd</sup> Gen first responder model as well as our 1st Gen in-hospital device.”

Authorised for release by the Board of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Andrew Keys  
Investor Relations  
+61 400 400 380  
Andrew.keys@keysthomas.com

Sling & Stone  
Media and Communications  
emvision@slingstone.com  
02 8073 5390

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## **About EMVision Medical Devices**

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.5 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

## **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.